Date: 2015-03-04
Type of information: Nomination
Compound:
Company: Warp Drive Bio (USA - MA)
Therapeutic area: Cancer - Oncology - Infectious diseases
Type agreement: nomination
Action mechanism:
Disease:
Details: * On March 4, 2015, Warp Drive Bio announced the appointment of Laurence Reid, Ph.D., to chief executive officer. Dr. Reid succeeds CEO and co-founder Gregory Verdine, Ph.D., who will continue to serve the company as president and chief scientific officer, as well as chairman of the company’s scientific advisory board. Dr. Verdine will also remain on Warp Drive Bio’s board of directors and will retain his appointment as a venture partner with Third Rock Ventures.
Dr. Reid brings to Warp Drive more than 25 years of experience in the global biopharmaceutical industry, with a focus on building innovative companies. He is an entrepreneur-in-residence at Third Rock Ventures, and most recently served as the chief business officer of Alnylam Pharmaceuticals, where he led various business functions, including business development, and established several transformative alliances for Alnylam. Prior to Alnylam, Dr. Reid served as chief business officer at Ensemble Therapeutics, where he
led the development and implementation of key business strategies for the company\'s therapeutic and diagnostic portfolios, as well as executed several major discovery alliances. Dr. Reid’s previous entrepreneurial experiences include the founding of startup companies in the fields of stem cell therapeutics and inflammation. He spent 10 years at Millennium Pharmaceuticals, Inc., where he worked in a range of general management and business development positions, including general manager of Millennium UK and vice president of business development for the company\'s predictive medicine efforts. Before joining Millennium, he was an assistant editor of the premier journal Cell. Dr. Reid holds a Ph.D. from London University and a B.A. from Cambridge University. He is a member of the board of directors of The Possible Project.
Financial terms:
Latest news:
